A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Metcalfe, John Z.; Weir, Isabelle R.; Scarsi, Kimberly K.; Mendoza-Ticona, Alberto et al.

Part of The Lancet - Infectious diseases, p. 46-54, 2026

• DOI for A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
• Download full text (pdf) of A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Stemkens, Ralf; Lemson, Arthur; Koele, Simon E.; Svensson, Elin M. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3100-3108, 2024

• DOI for A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
• Download full text (pdf) of A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

van Beek, Stijn W.; ter Heine, Rob; Alffenaar, Jan-Willem C.; Magis-Escurra, Cecile et al.

Part of Clinical Pharmacokinetics, p. 943-953, 2021

• DOI for A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
• Download full text (pdf) of A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Zou, Yuanxi; Nedelman, Jerry; Karlsson, Mats O.; Svensson, Elin M.

Part of Clinical Pharmacokinetics, p. 1357-1365, 2025

• DOI for A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection
• Download full text (pdf) of A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Wijk, Marie; Wasmann, Roeland E.; Jacobson, Karen R.; Svensson, Elin M. et al.

Part of CPT, p. 1042-1049, 2025

• DOI for A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
• Download full text (pdf) of A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis

Lin, Yu-Jou; Okibedi, Frances; Karlsson, Mats O.; Svensson, Elin M.

Part of CPT, 2026

• DOI for An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis
• Download full text (pdf) of An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis

Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

Dufault, Suzanne M.; Davies, Geraint R.; Svensson, Elin M.; Sloan, Derek J. et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification
• Download full text (pdf) of Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Ruth, Mike Marvin; van Rossum, Mara; Koeken, Valerie A. C. M.; Pennings, Lian J. et al.

Part of Antimicrobial Agents and Chemotherapy, 2019

• DOI for Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Raaijmakers, J.; Salillas, S.; Aarnoutse, R.; Svensson, Elin M. et al.

Part of Antimicrobial Agents and Chemotherapy, 2025

• DOI for Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
• Download full text (pdf) of Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Janssen, Saskia; Vongjarudech, Thanakorn; Karlsson, Mats O.; Upton, Caryn M. et al.

Part of Clinical Pharmacokinetics, p. 1885-1896, 2025

• DOI for Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
• Download full text (pdf) of Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Koele, Simon E.; Stoycheva, Krista; Mtweve, Cyprian; Manyama, Christina et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2305-2313, 2025

• DOI for Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
• Download full text (pdf) of Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Abulfathi, Ahmed Aliyu; Decloedt, Eric H.; Svensson, Elin M.; Diacon, Andreas H. et al.

Part of Clinical Pharmacokinetics, p. 1103-1129, 2019

• DOI for Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Brill, Margreke JE; Svensson, Elin M; Pandie, Mishal; Maartens, Gary et al.

Part of International Journal of Antimicrobial Agents, p. 212-217, 2017

• DOI for Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
• Download full text (pdf) of Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Yohane, M.; Naufal, F.; Endoza-Ticona, A. M.; Svensson, Elin M. et al.

Part of The International Journal of Tuberculosis and Lung Disease, p. 354-356, 2024

• DOI for Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Minja, Lilian Tina; van der Feltz, Isabella; Manyama, Christina; Mpagama, Stellah et al.

Part of The Lancet - Infectious diseases, p. 1219-1229, 2025

• DOI for Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
• Download full text (pdf) of Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Stemkens, Ralf; de Jager, Veronique; Dawson, Rodney; Diacon, Andreas H. et al.

Part of Antimicrobial Agents and Chemotherapy, 2023

• DOI for Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
• Download full text (pdf) of Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

Koele, Simon E.; Phillips, Patrick P. J.; Upton, Caryn M.; van Ingen, Jakko et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
• Download full text (pdf) of Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Karlsson, Mats O. et al.

Part of CPT, p. 1252-1261, 2025

• DOI for Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
• Download full text (pdf) of Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Svensson, Elin M.; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017

• DOI for Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Prins, H. A. B.; Zino, L.; Svensson, Elin M.; Verbon, A. et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)
• Download full text (pdf) of Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis

Abdelwahab, Mahmoud Tareq; Svensson, Elin M.; Diacon, Andreas H.; Conradie, Almarie et al.

Part of Antimicrobial Agents and Chemotherapy, 2026

• DOI for Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis
• Download full text (pdf) of Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis

First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis

Lutchmun, Wandini; Heinrich, Norbert; Svensson, Elin M.; Kloss, Florian et al.

Part of JAC - Antimicrobial Resistance, 2025

• DOI for First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis
• Download full text (pdf) of First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Gafar, Fajri; Wasmann, Roeland E.; McIlleron, Helen M.; Aarnoutse, Rob E. et al.

Part of European Respiratory Journal, 2023

• DOI for Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
• Download full text (pdf) of Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Svensson, Elin M.; Dooley, Kelly E.; Karlsson, Mats O.

Part of Antimicrobial Agents and Chemotherapy, p. 6406-6412, 2014

• DOI for Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Walter, Kerstin; te Brake, Lindsey H. M.; Lemm, Ann-Kathrin; Hoelscher, Michael et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2607-2610, 2024

• DOI for Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures
• Download full text (pdf) of Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Joint Modeling of Time to Positivity (TTP), Mycobacterium Tuberculosis - Molecular Bacterial Load Assay (TB-MBLA), and Lipoarabinomannan (PATHFAST TB LAM) antigen test: Quantifying Inter-Biomarker Correlations and Drug Effects in Pulmonary Tuberculosis

Vongjarudech, Thanakorn; Noreña, Iván; Njeleka, Fred; Mapamba, Daniel et al.

Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Susanto, Budi O.; Svensson, Elin M.; te Brake, Lindsey; Aarnoutse, Rob E. et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
• Download full text (pdf) of Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Svensson, Elin M.; Aweeka, Francesca; Park, Jeong-Gun; Marzan, Florence et al.

Part of Antimicrobial Agents and Chemotherapy, p. 2780-2787, 2013

• DOI for Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Kengo, Allan; Resendiz‐Galvan, Juan Eduardo; Najjemba, Letisha; Mugerwa, Henry et al.

Part of British Journal of Clinical Pharmacology, p. 3471-3481, 2025

• DOI for Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV
• Download full text (pdf) of Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Svensson, Elin M.; Dian, Sofiati; te Brake, Lindsey; Ganiem, Ahmad Rizal et al.

Part of Clinical Infectious Diseases, p. 1817-1823, 2020

• DOI for Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials
• Download full text (pdf) of Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Part of Clinical Pharmacology and Therapeutics, p. 1292-1302, 2025

• DOI for Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Download full text (pdf) of Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis

Svensson, Elin M; Rossenu, Stefaan; Karlsson, Mats O

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials

McClean, Mairi C. W.; Koele, Simon E.; Dreisbach, Julia; Mirold-Mei, Susanne et al.

Part of CPT, 2026

• DOI for Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials
• Download full text (pdf) of Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Svensson, Elin M.; Karlsson, Mats O

Part of Journal of Antimicrobial Chemotherapy, p. 3398-3405, 2017

• DOI for Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
• Download full text (pdf) of Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Svensson, Elin M.; Acharya, Chayan; Clauson, Björn; Dooley, Kelly E. et al.

Part of AAPS Journal, p. 171-179, 2016

• DOI for Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Pharmacometric Models to Improve Treatment of Tuberculosis

Svensson, Elin M

2016

• Download full text (pdf) of Pharmacometric Models to Improve Treatment of Tuberculosis

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Litjens, Carlijn H. C.; Verscheijden, Laurens F. M.; Svensson, Elin M.; van den Broek, Petra H. H. et al.

Part of Antibiotics, 2023

• DOI for Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
• Download full text (pdf) of Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Hennig, Stefanie; Svensson, Elin M; Niebecker, Ronald; Fourie, P Bernard et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1330-1340, 2016

• DOI for Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Gafar, Fajri; Svensson, Elin M.; Yunivita, Vycke; Fregonese, Federica et al.

Part of Journal of Infectious Diseases, 2026

• DOI for Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial
• Download full text (pdf) of Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Koele, Simon E.; Heinrich, Norbert; De Jager, Veronique R.; Dreisbach, Julia et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1315-1323, 2025

• DOI for Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
• Download full text (pdf) of Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Svensson, Elin M; Dosne, Anne-Gaëlle; Karlsson, Mats O

Part of CPT, p. 682-691, 2016

• DOI for Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin
• Download full text (pdf) of Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Svensson, Elin M.; Murray, Stephen; Karlsson, Mats O.; Dooley, Kelly E.

Part of Journal of Antimicrobial Chemotherapy, p. 1106-1114, 2015

• DOI for Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Rifampicin can be given as flat-dosing instead of weight-band dosing

Susanto, Budi Octasari; Svensson, Robin J.; Svensson, Elin M.; Aarnoutse, Rob et al.

Part of Clinical Infectious Diseases, p. 3055-3060, 2020

• DOI for Rifampicin can be given as flat-dosing instead of weight-band dosing
• Download full text (pdf) of Rifampicin can be given as flat-dosing instead of weight-band dosing

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Heinrich, Norbert; de Jager, Veronique; Dreisbach, Julia; Gross-Demel, Petra et al.

Part of The Lancet Microbe, 2025

• DOI for Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
• Download full text (pdf) of Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

van der Feltz, Isabella; Wen, Haini; Aarnoutse, Rob E.; Magis-Escurra, Cecile et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2597-2608, 2025

• DOI for Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
• Download full text (pdf) of Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Heinrich, Norbert; Manyama, Christina; Koele, Simon E.; Mpagama, Stellah et al.

Part of The Lancet - Infectious diseases, p. 1208-1218, 2025

• DOI for Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
• Download full text (pdf) of Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

The importance of getting the dose right in the treatment of tuberculosis

Dudnyk, Andrii; Lutchmun, Wandini; Duarte, Raquel; Lange, Christoph et al.

Part of Breathe, 2025

• DOI for The importance of getting the dose right in the treatment of tuberculosis
• Download full text (pdf) of The importance of getting the dose right in the treatment of tuberculosis

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Svensson, Elin M.; Svensson, Robin J.; te Brake, Lindsey H. M.; Boeree, Martin J. et al.

Part of Clinical Infectious Diseases, p. 34-41, 2018

• DOI for The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
• Download full text (pdf) of The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

Wen, Haini; Sadiq, Muhammad Waqas; Friberg, Lena E.; Svensson, Elin M.

Part of CPT, p. 796-806, 2025

• DOI for Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery
• Download full text (pdf) of Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

Meya, David B.; Cresswell, Fiona V.; Dai, Biyue; Engen, Nicole et al.

Part of New England Journal of Medicine, p. 2434-2446, 2025

• DOI for Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis